Immunofluorescence assays showed that Prx II and vimentin expression levels were reduced in vivo in miR-122-transfected tumor tissues compared with miR-NC-transfected tumor tissues, indicating that miR-122 targets Prx II and inhibits the EMT in A549/GR tumors (Fig. 5b, c). The gene discussed is VIM; the disease is neoplasm.